Get ready for a major evolution at the Medical Journal of Australia (MJA) starting in 2026! The journal is set to undergo a significant transformation, not just in its appearance but also in how it operates. This isn't just a facelift; it's a strategic reimagining designed to keep the MJA at the forefront of medical publishing and its core mission: delivering high-quality research and commentary that shapes health policy and influences medical practice across Australia.
As Professor Virginia Barbour, the Editor-in-Chief, explains, the MJA has been in deep reflection throughout 2025, charting a course for the future. "Journals are a human endeavor," she notes, emphasizing that the editorial team's priorities and values are the guiding force. The central challenge, common to all leading journals, is the delicate act of balancing the journal's capabilities with its core values and priorities. The goal? To consistently present a diverse array of content that resonates with the broadest possible audience of practitioners, researchers, and policymakers within the Australian health system.
But here's where it gets particularly interesting: The editorial team wields considerable power over what gets published, and they are keenly aware of the direct impact this has on authors' lives and careers. Their commitment is to foster a constructive and collaborative peer-review and publication process. Even for manuscripts that don't make the cut for review, the aim is to provide swift decisions and, where feasible, valuable feedback.
And this is the part most people miss: The inherent 'mathematics' of journal operations can create a tension between speed and thoroughness. Professor Barbour highlights a substantial increase in submissions over her three years as Editor-in-Chief, with a notable rise in international contributions. From 1413 submissions in 2023 to 1619 in 2025, the journal is seeing a global surge, with international submissions now accounting for nearly 33% of the total. This selective process means a crucial focus on papers that align perfectly with the journal's scope, minimizing time spent on those that won't be published.
Professor Barbour has identified four key categories into which submitted papers typically fall:
- Out of Scope: These are papers that, regardless of quality, simply don't address an issue relevant to Australian healthcare. This could be due to the study population, setting, health topic, or being too pre-clinical. Alarmingly, some of these submissions show clear signs of being products of "paper mills." Authors submitting in this category are urged to reconsider, as these papers will never be published and consume valuable editorial time.
- Not a High Priority: While potentially relevant to Australian healthcare, these papers don't meet the journal's high-priority qualitative criteria. These criteria, detailed in author and reviewer guidance, include a high burden of disease in Australia, significant public health interest, research or commentary led by Aboriginal and Torres Strait Islander peoples, or topics likely to have an immediate impact on clinical practice or policy.
- Fundamental Issues Identified: These papers might align with the qualitative criteria but contain design or writing flaws that indicate fundamental problems. These could range from concerns about research rigor, interpretive difficulties due to design or analysis, ethical or governance issues, poor reporting (e.g., not using reporting guidelines), or lack of access to underlying data. For non-research manuscripts, a common pitfall is a weak grounding in existing literature. These are often the most challenging to assess.
- Publication Candidates: These are the papers that perfectly fit the criteria, appear well-written and reported on initial review, and present no obvious barriers to publication. These are the manuscripts selected for peer review, and if no significant issues arise, they are published.
So, how does this all tie into the 2025 strategy? Understanding these submission dynamics is key to planning more efficient editorial processes.
The first major shift is a restructured editorial team. Beginning in 2026, the MJA's in-house manuscript decision-making body will include the Editor-in-Chief, Deputy Editor, two Senior Editors, and, in a novel move, five part-time Associate Editors. These Associate Editors will contribute one day a week alongside their existing clinical or academic roles, aiming to broaden the MJA's reach into Australia's research and healthcare communities and bolster editorial capacity. The vision is to cultivate a strong cohort of clinicians and academics with editorial experience.
This leads to a more selective approach to external peer review. Recognizing the precious time of reviewers, the MJA hopes this refinement will be welcomed. By sending fewer papers for review, the hope is that reviewers can dedicate more focused attention to the manuscripts they do evaluate. For papers rejected without peer review, decisions will be expedited.
Changes are also being made to post-review and acceptance processes. The team will now comprise a Managing Editor and a Publishing Project Editor. While minor edits for typos and inconsistencies will continue, extensive structural editing after acceptance will be phased out. The focus will shift to closer collaboration with authors before acceptance, minimizing post-acceptance revisions. This practical change means accepted papers will be published online much faster.
Finally, expect a visual and structural refresh! The journal's layout, individual article presentation, and publishing cadence are evolving. This has already begun with a new PDF format, and articles are now published continuously rather than being tied to specific issue dates. Monthly compiled issues will replace the previous 22 issues per year, starting in January 2026. Furthermore, a complete website redesign is slated for mid-2026 to enhance display and functionality.
These changes have been meticulously planned, with the hope that authors and readers will experience only positive outcomes. As always, feedback is warmly welcomed. The MJA remains committed to its mission of providing high-quality evidence and insights to advance Australian healthcare and health equity.
A point of potential debate: With the increased selectivity and streamlined processes, will the MJA risk overlooking promising research that might not perfectly fit the established criteria? Or will this focus allow for deeper engagement with the papers that do align, ultimately leading to higher impact publications? What are your thoughts on this strategic shift? Do you believe this approach will better serve the Australian health community?
